Tandutinib

Search with Google Search with Bing

Information
Drug Name
Tandutinib
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
acute myeloid leukemia FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		D Predictive Supports Resistance Somatic 3 15256420 Detail
cancer KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 16046538 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Murine Ba/F3 cells with FLT3-D835V mutations were ... FLT3 FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		Resitance or Non-Reponse true CIViC Evidence detail
KIT(V559D) were expressed in HEK-293 cells (in vit... KIT KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT00379080 Completed Phase 1/Phase 2 Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma January 2007 June 2013
NCT00390468 Completed Phase 2 Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases October 2006 November 2009
NCT00408902 Completed Phase 2 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer November 2006 December 2008
NCT00297921 Withdrawn Phase 1/Phase 2 A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy